Evaluating the safety of a rotavirus vaccine: the REST of the story

Abstract

The Rotavirus Efficacy and Safety Trial (REST) was a blinded, placebo-controlled study of the live pentavalent human-bovine vaccine, RotaTeq^® (Merck & Co. Inc., West Point, PA). REST was noteworthy because its primary objective was to evaluate the safety of RotaTeq^® with regard to intussusception, a rare intestinal illness that occurs with a background incidence of approximately 50 cases per 100 000 infant years. The study involved approximately 70 000 infants at over 500 study sites in 11 countries. The study demonstrated that the risk of intussusception was similar in vaccine and placebo recipients and that the vaccine prevented rotavirus gastroenteritis, ameliorated the severity of disease in those who had any disease, and substantially reduced rotavirus-associated hospitalizations and other health care contacts. This report provides an in-depth review of the background, statistical and regulatory considerations, and execution of REST. We describe the rationale and methods used for sample size, continuous safety monitoring, group sequential design, and detailed study execution. The results of the study have been reported elsewhere. The design and conduct of this study may serve as a useful model for planning other future large-scale clinical trials, especially those evaluating uncommon adverse events. Clinical Trials 2008; 5: 131—139. http:// ctj.sagepub.com

References

Parashar UD , Hummelmann EG , Bresee JS , et al. Global illness and deaths caused by rotavirus disease in children . Emerg Infect Dis 2003; 9: 565-72.

Bresee JS , Glass RJ , Ivanoff B. , Gentsch JR Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries . Vaccine 1999; 17: 2207-22.

Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children: recommendations of the Advisory Committee on Immunization Practices . MMWR Recomm Rep 1999; 48(RR-2): 1-20.

Saez-Llorens X. , Nieto Guevara J.

Intussusception and rotavirus vaccines: what is the background risk?

Ped Infect Dis J 2004; 23(4): 363-65.

Intussusception among recipients of rotavirus vaccine - United States, 1998-1999 . MMWR Morb Mortal Wkly Rep 1999; 48: 577-81.

Kramarz P. , France EK , Destefano F. , et al. Population-based study of rotavirus vaccination and intussusception . Pediatr Infect Dis J 2001; 204: 10-16.

Murphy TV , Gargiullo PM , Massoudi MS , et al. Intussusception among infants given an oral rotavirus vaccine . N Engl J Med 2001; 344(8): 564-72.

Parashar UD , Holman RC , Cummings KC , et al. Trends in intussusception-associated hospitalizations and deaths among US infants . Pediatrics 2000; 106: 1413-21.

Rennels MB , Parashar UD , Holman RC , et al. Lack of an apparent association between intussusception and wild or vaccine rotavirus infection . Pediatr Infect Dis J 1998; 17: 924-25.

10.

Haber P. , Chen RT , Zanardi LR , et al. An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone ? Pediatrics 2004; 113(4): 3353-59.

11.

Joensuu J. , Koskenniemi E. , Pang XL , Vesikari T. Randomized placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis . Lancet 1997; 350: 1205-09.

12.

Joensuu J. , Koskenniemi E. , Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants . Pediatr Infect Dis J 1998; 17: 334-40.

13.

Rennels MB , Glass RI , Dennehy PH , et al. Safety and efficacy of high-dose rhesus human reassortant rotavirus vaccines - report of the National Multicenter Trial: United States Rotavirus Vaccine Efficacy Group . Pediatrics 1996; 97: 7-13.

14.

Vesikari T. , Clark HF , Offit PA , et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants . Vaccine 2006; 24: 4821-29.

15.

Peter G. , Myers MG Intussusception, rotavirus and oral vaccines: summary of a workshop . Pediatrics 2002; 110(6): e67 .

16.

Glass RJ , Bresee JS , Parashar UD , et al. The future of rotavirus vaccines: a major setback leads to new opportunities . Lancet 2004; 363: 1547-50.

17.

Heaton PM , Goveia MG , Miller JM , et al. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis . J Infect Dis 2005; 192 (Suppl 1): S17-S21.

18.

Chang EJ , Zangwill KM , Lee H. , et al. Lack of association between rotavirus infection and intussusception implications for use of attenuated rotavirus vaccines . Pediatr Infect Dis J 2002; 21: 97-102.

19.

Uhnoo I. , Riepenhoff-Talty M. , Dharakul T. , et al. Extramural spread and development of hepatitis in immunodeficient and normal mice infected with rhesus rotavirus . J Virol 1990; 64(1): 361-68.

20.

Vesikari T. , Matson DO , Dennehy P. , et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine . New Engl J Med 2006; 354: 23-33.

21.

Jennison C. , Turnbull BW Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall/CRC, Boca Raton, FL, 2000 .

22.

Ellenberg SS , Foulkes MA , Midthun K. , et al. Evaluating the safety of new vaccines: summary of a workshop . Am J Public Health 2005; 95(5): 800-07.